Who is sponsoring NCT03431753?

NCT03431753 is sponsored by Aarhus University Hospital.

What condition does NCT03431753 study?

NCT03431753 studies Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma.

What drugs are being tested in NCT03431753?

Interventions: PSA, STHLM3 and mpMRI for PC detection.

What is the status of NCT03431753?

NCT03431753 is currently UNKNOWN.

Last reviewed 2021-05-04 · How we verify

Early and Accurate Detection of Prostate Cancer in General Practice

NCT03431753 NA UNKNOWN

Prostate cancer (PC) is the most common malignancy (4500 new cases/year) and the second leading cause of cancer-associated mortality (1200 deaths/year) among men in Denmark. PC is generally diagnosed on the basis of an elevated prostate specific antigen blood test followed by transrectal ultrasound (TRUS)-guided prostate biopsy. This study aims to test early detection of PC in general practice, using the STHLM3 model with superior specificity and sensitivity for clinically significant PC, combined with multiparametric magnetic resonance imaging (mpMRI) of the prostate and MR guided biopsy.

Details

Lead sponsor	Aarhus University Hospital
Phase	NA
Status	UNKNOWN
Enrolment	3000
Start date	Mon Jan 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Prostate Cancer
Prostate Neoplasm
Prostate Adenocarcinoma

Interventions

PSA, STHLM3 and mpMRI for PC detection

Countries

Denmark